Independent
Tenure on this board
4.7 yrs
Meeting calendar
SABS · Annual meeting · Thursday, July 17, 2025
Sab Biotherapeutics Inc
4 nominees · 3 ballot items.
Election of four Class I directors; ratification of EisnerAmper LLP as SAB Biotherapeutics, Inc.'s independent registered public accounting firm for 2025; and authorization to transact any other business as may properly come before the Annual Meeting.
Market cap
$297M
1Y TSR
+100.9%
Board grade
C
Record date
May 20, 2025
Filing
DEF 14A
Meeting concluded · Jul 17, 2025
Follow how the vote landed and what changed on Sab Biotherapeutics Inc’s board — director track records, governance grades, and ongoing monitoring — on the Boardroom Alpha platform.
Proposals
On the ballot3
- 1
Election of four Class I directors to serve for a three-year term expiring at the 2028 annual meeting
ManagementBoard: FORElection of four Class I directors: William Polvino, Scott Giberson, Erick Lucera and Jay S. Skyler to serve three-year terms.
- 2
Ratification of the appointment of EisnerAmper LLP as independent registered public accounting firm
ManagementBoard: FORRatify EisnerAmper LLP as SAB Biotherapeutics, Inc.'s independent registered public accounting firm for fiscal year ending December 31, 2025.
- 3
Transact any other business as may properly come before the Annual Meeting or any adjournment or postponement of the Annual Meeting
ManagementAuthorize proxies to vote on any other matters properly brought before the meeting.
Director elections
Nominees on the ballot4
Independent
Tenure on this board
4.0 yrs
Independent
Tenure on this board
3.3 yrs
Also a director at
Beyond Air Inc (XAIR)
Jay S. Skyler, M.D., MACP, FRCP
Independent
Tenure on this board
New nominee
Ownership
Latest 13F quarterTop institutional holders10
| # | Owner | % of shares | Shares | Value |
|---|---|---|---|---|
| 1 | Vivo Capital, LLC | 14.9% | 11,420,000 | $44M |
| 2 | Caligan Partners LPActivist | 10.4% | 7,967,207 | $31M |
| 3 | PERCEPTIVE ADVISORS LLC | 8.4% | 6,431,743 | $25M |
| 4 | Commodore Capital LP | 5.8% | 4,401,500 | $17M |
| 5 | RA CAPITAL MANAGEMENT, L.P. | 5.8% | 4,401,500 | $17M |
| 6 | BALYASNY ASSET MANAGEMENT L.P. | 4.9% | 3,760,439 | $14M |
| 7 | ADAGE CAPITAL PARTNERS GP, L.L.C. | 4.5% | 3,405,553 | $13M |
| 8 | MILLENNIUM MANAGEMENT LLC | 4.0% | 3,032,697 | $12M |
| 9 | Woodline Partners LP | 3.7% | 2,851,791 | $11M |
| 10 | VANGUARD CAPITAL MANAGEMENT LLC | 3.3% | 2,493,737 | $10M |
Peers
Nearest market capOther Healthcare sector meetings6
Upcoming shareholder meetings at Sab Biotherapeutics Inc’s closest sector peers — compare boards, ballots, and ownership across the cohort.
Trubridge IncTBRG
Special meeting·Jul 7, 2026·$393M
Cross Country Healthcare IncCCRN
Special meeting·Jul 16, 2026·$427M
Seer IncSEER
Annual meeting·Jul 28, 2026·$91M
Xoma Royalty CorpXOMA
Annual meeting·Jul 13, 2026·$533M
Achieve Life Sciences IncACHV
Annual meeting·Jul 2, 2026·$670M
Aura Biosciences IncAURA
Special meeting·Aug 5, 2026·$734M
Reference
Frequently asked questions
- When is the Sab Biotherapeutics Inc 2025 annual meeting?
- Sab Biotherapeutics Inc (SABS) holds its 2025 annual shareholder meeting on Thursday, July 17, 2025.
- What is the record date for the Sab Biotherapeutics Inc 2025 meeting?
- The record date for the Sab Biotherapeutics Inc 2025 meeting is Tuesday, May 20, 2025. Shareholders of record on or before that date are eligible to vote.
- Who are the director nominees for Sab Biotherapeutics Inc's 2025 meeting?
- The board is presenting 4 director nominees at the Sab Biotherapeutics Inc 2025 meeting, listed with their independence status and background.
- What proposals will shareholders vote on at the Sab Biotherapeutics Inc 2025 meeting?
- Shareholders will vote on 3 proposals at the Sab Biotherapeutics Inc 2025 meeting, each tagged with who proposed it and the board's recommendation.
Disclaimer
The opinions and information contained herein have been obtained or derived from sources believed to be reliable, but Boardroom Alpha cannot guarantee its accuracy and completeness, and that of the opinions based thereon.
This report contains opinions and is provided for informational purposes only – it does not constitute investment, legal or tax advice. You should not rely solely upon the research herein for purposes of transacting securities or other investments, and you are encouraged to conduct your own research and due diligence, and to seek the advice of a qualified securities professional before you make any investment.
None of the information contained in this report constitutes, or is intended to constitute a recommendation by Boardroom Alpha of any particular security or trading strategy or a determination by Boardroom Alpha that any security or trading strategy is suitable for any specific person. To the extent any of the information contained herein may be deemed to be investment advice, such information is impersonal and not tailored to the investment needs of any specific person.
No representation or warranty, expressed or implied, is made on behalf of Boardroom Alpha as to the accuracy or completeness of the information contained herein. Boardroom Alpha does not accept any liability for any direct, indirect or consequential loss or damage suffered by any person as a result of relying on all or any part of this research and any liability is expressly disclaimed.